production commence end of q1, page-13

Thanks, Booster. Took a while:) It's inconceivable, to my mind at least, that the requirement for ageing studies wasn't/hasn't been factored into their forward planning. It's not like they woke up one morning and realised, OMG, we need to conduct ageing studies! Why didn't we think of that? :)

So, up-front Exclusive License fees for Unifill from half a dozen or so big pharma produce significant chunks of cash, taking care of revenue requirements while the ageing studies are completed and sufficient stock is produced to meet anticipated requirements.

And that's not taking into account similar payments for Select, and possibly even the Tuberculin.

So, when the Licence fees are announced, followed by Supply Agreements, and details of revenue sharing for the Generic/Patent Cliff market, perhaps the market will FINALLY wake up to the reality and size of the opportunity on offer! :)

That aaid, I do agree that's it's something that hasn't been communicated as effectively as it might.

Not to worry, the silver lining is that we still have a great window of opportunity to accumulate. I know we've said it before, but it won't last forever!